Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Research & Development (2020 - 2025)

Bioventus' Research & Development history spans 6 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Research & Development fell 8.07% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $12.1 million, down 13.17%, while the annual FY2025 figure was $12.1 million, 13.17% down from the prior year.
  • Research & Development reached $3.0 million in Q4 2025 per BVS's latest filing, up from $2.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $7.1 million in Q4 2021 to a low of $947000.0 in Q2 2021.
  • Average Research & Development over 5 years is $4.1 million, with a median of $3.6 million recorded in 2023.
  • Peak YoY movement for Research & Development: crashed 55.87% in 2021, then skyrocketed 631.57% in 2022.
  • A 5-year view of Research & Development shows it stood at $7.1 million in 2021, then decreased by 16.29% to $5.9 million in 2022, then tumbled by 45.14% to $3.3 million in 2023, then grew by 0.28% to $3.3 million in 2024, then fell by 8.07% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Research & Development are $3.0 million (Q4 2025), $2.9 million (Q3 2025), and $3.2 million (Q2 2025).